[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Sarper N, Ozbek U, Ağaoğlu L, Ozgen U, Eryilmaz E, Yalman N, Anak S, Devecioğlu O, Gedikoğlu G: Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia? Pediatr Hematol Oncol; 2000 Oct-Nov;17(7):577-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia?
  • To assess the clinical significance of AML1/ETO gene detected by nested reverse transcriptase polymerase chain reaction, the outcome of 7 patients with acute myeloblastic leukemia between 3 and 14 years of age were presented.
  • All relapsed patients died between 18 and 36 months with resistant disease (n = 3) or infection during salvage chemotherapy (n = 1).
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Bone Marrow Transplantation. Child. Child, Preschool. Combined Modality Therapy. Core Binding Factor Alpha 2 Subunit. Disease-Free Survival. Female. Gene Expression. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / therapy. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / metabolism. Leukemia, Myelomonocytic, Acute / therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / therapy. Male. RNA, Messenger / analysis. RNA, Messenger / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11033733.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


2. Ehlert K, Groll AH, Kuehn J, Vormoor J: Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr; 2006 May-Jun;218(3):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
  • BACKGROUND: Treatment of cytomegalovirus (CMV) disease after allogeneic hematopoietic stem cell transplantation (HSCT) is limited by toxicities of current antiviral drugs and the occurrence of drug resistant strains.
  • Leflunomide, an immunosuppressive agent used for treatment of rheumatoid arthritis, also has activity against CMV by impairing viral assembly.
  • PATIENTS AND RESULTS: A 1S-year-old boy with juvenile myelo-monocytic leukemia (JMML) received an allogeneic HSCT with bone marrow stem cells from a mismatched, unrelated donor (MMUD, recipient and donor CMV-positive).
  • CONCLUSION: This case report suggests that leflunomide may be of use in the management of transplant recipients with CMV-infection refractory or intolerant to conventional antiviral therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytomegalovirus Infections / drug therapy. Foscarnet / therapeutic use. Hematopoietic Stem Cell Transplantation. Isoxazoles / therapeutic use. Leukemia, Myelomonocytic, Acute / therapy. Opportunistic Infections / drug therapy
  • [MeSH-minor] Bone Marrow Purging. Cytomegalovirus / drug effects. Drug Resistance, Viral. Drug Therapy, Combination. Humans. Immunosuppression. Infant. Male. Retreatment

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. Foscarnet .
  • Hazardous Substances Data Bank. LEFLUNOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688677.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Isoxazoles; 364P9RVW4X / Foscarnet; G162GK9U4W / leflunomide
  •  go-up   go-down


3. Schiavetti A, Varrasso G, Maurizi P, Castello MA: Two secondary leukemias among 15 children given oral etoposide. Med Pediatr Oncol; 2001 Aug;37(2):148-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Etoposide / adverse effects. Leukemia, Monocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Child. Humans. Neuroblastoma / drug therapy

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496357.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


Advertisement
4. Bakshi C, Amare Kadam P, Abhyankar D, Baisane C, Banavali S, Advani S: Chromosomal rearrangement in Down syndrome with acute myeloid leukemia. Indian J Pediatr; 2003 Sep;70(9):755-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal rearrangement in Down syndrome with acute myeloid leukemia.
  • The incidence of acute leukemia in children with Down syndrome (DS) is high as compared to general population.
  • Recent findings have demonstrated that DS children with acute myeloid leukemia (AML) have the highest event free survival rates with high dose cytosine arabinoside (Ara-C).
  • We present 3 year-old DS female child with AML-M5, whose chromosomal analysis revealed constitutional t(21;21) alongwith del(5)(q31q33) and a unique translocation t(16;20)(q13;q12).
  • After chemotherapy, child achieved complete clinical remission.
  • This case alongwith supportive literature indicate that pediatric DS-AML is a distinct biologic sub-group differs from that of non-DS-AML with respect to chemosensitivity.
  • [MeSH-major] Chromosome Aberrations. Down Syndrome / genetics. Leukemia, Monocytic, Acute / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Chromosome Deletion. Cytarabine. Daunorubicin / administration & dosage. Daunorubicin / therapeutic use. Female. Humans. Thioguanine. Translocation, Genetic

  • Genetic Alliance. consumer health - Down Syndrome.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):160-4 [7828147.001]
  • [Cites] Am J Hematol. 1989 Aug;31(4):273-9 [2525873.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):211-30 [2978961.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):87-94 [9598794.001]
  • [Cites] Clin Genet. 1984 Aug;26(2):117-24 [6147215.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Feb;51(2):277-8 [1993313.001]
  • [Cites] Cell. 1994 Apr 22;77(2):307-16 [8168137.001]
  • [Cites] Hematol Oncol. 1991 Jan-Feb;9(1):17-32 [2045068.001]
  • (PMID = 14620194.001).
  • [ISSN] 0019-5456
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


5. Corazza F, Hermans C, Ferster A, Fondu P, Demulder A, Sariban E: Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatr Res; 2004 Jan;55(1):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children.
  • Several studies have suggested a role of bone marrow stroma injury in long-term chemotherapy-induced hematopoietic failure.
  • To evaluate whether bone marrow microenvironment is altered by chemotherapy for acute lymphoblastic leukemia (ALL) and to determine its contribution to postchemotherapy anemia, we investigated the ability of stroma from children receiving maintenance chemotherapy for ALL to support hematopoiesis.
  • Long-term bone marrow cultures (LTBMC) were established with bone marrow cells either from ALL children under therapy (n = 24) or from control subjects (n = 19).
  • Nonadherent cells and colony forming units-granulocytic monocytic (CFU-GM) output in LTBMC did not differ between patients and controls.
  • Thus, chemotherapy for ALL induces functional deregulation within bone marrow stromal cells with an increase in the growth-inhibiting factor TGF-beta1, together with a decrease in MIP-1alpha, which might contribute to hematopoietic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Stromal Cells / drug effects
  • [MeSH-minor] 6-Mercaptopurine / adverse effects. Antibodies / pharmacology. Antigens, CD34 / metabolism. Antimetabolites, Antineoplastic / adverse effects. Cells, Cultured. Chemokine CCL3. Chemokine CCL4. Child. Chronic Disease. Coculture Techniques. Cytokines / immunology. Erythroid Precursor Cells / drug effects. Erythroid Precursor Cells / metabolism. Erythroid Precursor Cells / pathology. Humans. Macrophage Inflammatory Proteins / immunology. Methotrexate / adverse effects. Myeloid Progenitor Cells / drug effects. Myeloid Progenitor Cells / metabolism. Myeloid Progenitor Cells / pathology. Transforming Growth Factor beta / immunology. Transforming Growth Factor beta1

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561785.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD34; 0 / Antimetabolites, Antineoplastic; 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Cytokines; 0 / Macrophage Inflammatory Proteins; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Langebrake C, Klusmann JH, Wortmann K, Kolar M, Puhlmann U, Reinhardt D: Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. Haematologica; 2006 Nov;91(11):1473-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome.
  • BACKGROUND AND OBJECTIVES: Myeloid leukemia of Down's syndrome (ML-DS) has characteristic biological features (e.g. expression of the truncated GATA1s), which are different from those of non-DS childhood acute myeloid leukemias (AML).
  • DESIGN AND METHODS: We analyzed 134 bone marrow specimens from 64 children with ML-DS and non-DS AML during chemotherapy and 7 specimens from DS children with- out leukemia,who did not receive any chemotherapy,The specimens were analyzed by multiparameter flow cytometry and quantitative reverse transcriptase polymerase chain reaction for transcription factors involved in hematopoiesis.
  • RESULTS: Samples taken from children with ML-DS in complete remission during chemotherapy aberrantly expressed CD56 (NCAM) at the surface of monocytic and granulocytic cells.
  • A significant decrease of the amount of CD33+/CD56+ cells was observed during and after maintenance therapy.
  • An increased number of CD33+/CD56+ cells was also present (>85%) in children with DS who did not receive chemotherapy, but showed a left-shift (due to infection), compared with DS children without left-shift (<10% CD33+/CD56+ cells).
  • INTERPRETATION AND CONCLUSIONS: The combined overexpression of RUNX1 and NCAM during stress hematopoiesis in children with DS might be a key factor in the development of overt leukemia and/or in the growth advantage of the malignant GATA1s clone in ML- DS.
  • [MeSH-major] Bone Marrow Cells / metabolism. Core Binding Factor Alpha 2 Subunit / biosynthesis. Down Syndrome / metabolism. Leukemia, Myeloid / metabolism. Neural Cell Adhesion Molecules / biosynthesis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043020.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Neural Cell Adhesion Molecules; 0 / RUNX1 protein, human
  •  go-up   go-down


7. Hijiya N, Metzger ML, Pounds S, Schmidt JE, Razzouk BI, Rubnitz JE, Howard SC, Nunez CA, Pui CH, Ribeiro RC: Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer; 2005 Jan;44(1):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia.
  • BACKGROUND: Life-threatening pulmonary complications that coincide with cell lysis during early chemotherapy and that mimic systemic inflammatory response syndrome (SIRS) have been reported in patients with acute myeloid leukemia (AML).
  • RESULTS: Of 155 patients, 5 (3 with M4eo and 2 with M5) experienced severe pulmonary complications attributed to tumor lysis, met the criteria for severe SIRS, and showed no clear evidence of infection.
  • Severe SIRS was significantly more common in myelomonocytic or monocytic AML (M4/M4eo/M5) than in other subtypes (P = 0.010) and significantly more common in M4eo than in M4/M5 (P = 0.008).
  • Among 112 cases for which information was available, leukocyte reduction was significantly greater in patients with M4/M4eo/M5 than among others during the first 4 days of chemotherapy (P = 0.015).
  • CONCLUSIONS: Patients with M4/M4eo/M5 AML, especially M4eo, experience life-threatening cardiopulmonary complications of tumor lysis that meet the criteria for severe SIRS.
  • [MeSH-major] Cell Death. Leukemia, Monocytic, Acute / complications. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / complications. Leukemia, Myelomonocytic, Acute / drug therapy. Systemic Inflammatory Response Syndrome / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Male. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15368547.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


8. Miura M, Yachie A, Hashimoto I, Okabe T, Murata N, Fukuda A, Koizumi S: Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero. J Pediatr Hematol Oncol; 2000 Jan-Feb;22(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero.
  • Congenital leukemia often provides insight into mechanisms of in utero leukemogenesis.
  • A 10-day-old boy with clinical features of skin nodules, marked hepatosplenomegaly, and subcutaneous bleeding received a diagnosis of congenital leukemia.
  • Treatment with prednisolone, vincristine, and doxorubicin resulted in a loss of lymphoblast population and a rapid increase and dominance of the monocyte component within 10 days.
  • Complete remission initially was obtained with additional combination chemotherapy with epipodophyllotoxin (VP-16) and cytosine arabinoside (Ara-C), but relapse characterized by a lymphoblastic population in the bone marrow was subsequently observed.
  • [MeSH-major] Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Leukemia, B-Cell / congenital. Leukemia, B-Cell / pathology. Leukemia, Monocytic, Acute / congenital. Leukemia, Monocytic, Acute / pathology. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10695828.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


9. Bernard F, Thomas C, Emile JF, Hercus T, Cassinat B, Chomienne C, Donadieu J: Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood; 2002 Apr 1;99(7):2615-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia.
  • Juvenile chronic myelomonocytic leukemia (JMML) is a rare leukemia where spontaneous proliferation of myeloid and monocytic precursors in patients' bone marrow cultures is dependent on GM-CSF.
  • For patients who progress after systemic chemotherapy, there are no effective therapies.
  • E21R was well-tolerated during the 3 courses of subcutaneous treatment.
  • This novel therapeutic approach clearly deserves further evaluation in JMML.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Leukemia, Myelomonocytic, Acute / genetics
  • [MeSH-minor] Amino Acid Substitution. Arginine. Child. Drug Monitoring. Glutamic Acid. Humans. Male. Mutation, Missense. Treatment Outcome

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11895804.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3KX376GY7L / Glutamic Acid; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 94ZLA3W45F / Arginine
  •  go-up   go-down


10. Chantrain CF, Sauvage D, Brichard B, Dupont S, Poirel HA, Ameye G, De Weer A, Vandenberghe P, Detaille T, Anslot C, de Cléty SC, Vermylen C: Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. Pediatr Blood Cancer; 2009 Aug;53(2):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero.
  • We report on an acute myeloid leukemia in a neonate whose mother was exposed to diethylstilboestrol in utero.
  • The newborn presented with leukemia cutis, hemorrhagic skin lesions, hyperleucocytosis and disseminated intravascular coagulation.
  • A bone marrow examination confirmed the diagnosis of acute monocytic leukemia with a t(11;19) MLL-ELL fusion transcript.
  • Chemotherapy was initiated but the child developed a bilateral pulmonary infection that led to fatal respiratory distress.
  • This case shows acute myeloid leukemia and the third pediatric leukemia reported after maternal diethylstilboestrol exposure.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Prenatal Exposure Delayed Effects / chemically induced
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. In Situ Hybridization, Fluorescence. Infant, Newborn. Infertility, Female / chemically induced. Male. Mothers. Myeloid-Lymphoid Leukemia Protein. Oncogene Proteins, Fusion. Pedigree. Pregnancy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19405140.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 0 / MLL-ELL fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


11. Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI: Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hematol Oncol; 2002 Nov;24(8):677-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure.
  • The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA.
  • The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.
  • Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction.
  • [MeSH-major] Acute Kidney Injury / metabolism. Antimetabolites, Antineoplastic / pharmacokinetics. Cladribine / pharmacokinetics. Hemofiltration. Leukemia, Monocytic, Acute / drug therapy. Renal Dialysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / complications. Child. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukapheresis. Male. Metabolic Clearance Rate. Recombinant Proteins / therapeutic use. Remission Induction. Urate Oxidase / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439044.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; 6PLQ3CP4P3 / Etoposide; EC 1.7.3.3 / Urate Oxidase; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


12. Malbora B, Senel E, Avci Z, Ozbek N: Purpuric nodules and macules on the scalp of an 18-month-old boy. Skinmed; 2010 Sep-Oct;8(5):305-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 18-month-old boy was consulted to a pediatric clinic with a 5-month history of purpuric macules and nodules on the scalp.
  • Cranial computed tomography revealed a small crack on the temporal bone.
  • Bone marrow aspirate results showed 68.4% blast cells and a biopsy specimen confirmed the diagnosis of acute myeloid leukemia, with flow cytometry findings positive for acute monoblastic leukemia (AML) French-American-British (FAB)-M5 phenotype.
  • We initiated induction chemotherapy for AML (AML-M5) according to the AML Berlin-Frankfurt-Munster 2004 protocol.
  • ' Complete resolution of the leukemia cutis lesions was attained with chemotherapy at the end of the first month of treatment.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Scalp Dermatoses / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, CD45 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Agents / therapeutic use. Blood Cell Count. Flow Cytometry. Humans. Infant. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Skinmed. 2011 Jan-Feb;9(1):66
  • (PMID = 21137646.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD68 antigen, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


13. Ozyurek E, Arda S, Ozkiraz S, Alioglu B, Arikan U, Ozbek N: Febrile neutropenia as the presenting sign of appendicitis in an adolescent with acute myelogenous leukemia. Pediatr Hematol Oncol; 2006 Apr-May;23(3):269-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia as the presenting sign of appendicitis in an adolescent with acute myelogenous leukemia.
  • The diagnosis and management of a surgical abdomen in patients with acute leukemia is quite difficult because of the complications and treatment of disease itself.
  • A 13-year-old boy with acute myelogenous leukemia developed 2 episodes of febrile neutropenia during induction therapy.
  • The second one was treated with a 5-day course of parenteral antimicrobial therapy, but the patient then presented with right lower quadrant abdominal tenderness, guarding, and rebound tenderness.
  • Abdominal ultrasonography and computed tomography revealed appendicitis.
  • The case illustrates that fever may be the first manifestation of appendicitis in a child with acute myelogenous leukaemia who is neutropenic.
  • Surgery is acceptable as first-line treatment in such cases.
  • [MeSH-major] Abdomen, Acute / etiology. Appendicitis / diagnosis. Enterocolitis, Necrotizing / diagnosis. Fever / etiology. Leukemia, Monocytic, Acute / complications. Neutropenia / complications
  • [MeSH-minor] Adolescent. Amikacin / therapeutic use. Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Cephalosporins / therapeutic use. Combined Modality Therapy. Diagnostic Errors. Drug Therapy, Combination. Humans. Male. Ornidazole / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. AMIKACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517543.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins; 62XCK0G93T / Ornidazole; 7XU7A7DROE / Amphotericin B; 807PW4VQE3 / cefepime; 84319SGC3C / Amikacin
  •  go-up   go-down


14. Sandoval C, Katz B, Stringel G, Jayabose S, Lebovics E: Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase. J Pediatr Hematol Oncol; 2003 Aug;25(8):637-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 2 children with acute leukemia who developed symptomatic cholelithiasis and choledocholithiasis shortly after receiving sequential high-dose cytarabine and asparaginase.
  • These children did not experience any unusual therapy-related hepatic toxicity after laparoscopic cholecystectomy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / adverse effects. Cholelithiasis / chemically induced. Cytarabine / adverse effects
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Leukemia, Monocytic, Acute / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Gallstones.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902918.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


15. Uram R, Rosoff PM: Isolated IgA deficiency after chemotherapy for acute myelogenous leukemia in an infant. Pediatr Hematol Oncol; 2003 Sep;20(6):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated IgA deficiency after chemotherapy for acute myelogenous leukemia in an infant.
  • Intensive chemotherapy for acute leukemia is also profoundly immunosuppressive and can be complicated with life-threatening infections, usually associated with neutropenia and prolonged lymphopenia in the post-bone marrow transplant setting.
  • Isolated, acquired immunoglobulin deficiency that occurs during treatment has been described but is usually transient.
  • In this report, the authors describe a patient with infant acute myelogenous leukemia with acquired, persistent IgA deficiency.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. IgA Deficiency / chemically induced. Leukemia, Monocytic, Acute / complications
  • [MeSH-minor] Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Immunoglobulins, Intravenous / therapeutic use. Infant. Male. Thioguanine / administration & dosage. Thioguanine / adverse effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631625.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin; DCTER protocol
  •  go-up   go-down


16. Tirado CA, Valdez F, Klesse L, Karandikar NJ, Uddin N, Arbini A, Fustino N, Collins R, Patel S, Smart RL, Garcia R, Doolittle J, Chen W: Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review. Cancer Genet Cytogenet; 2010 Jul 1;200(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.
  • Coexistence of inv(16) and t(9;22) is a rare chromosomal aberration, one that has been described in chronic myelogenous leukemia (CML), mainly in myeloid blast crisis, and de novo acute myeloid leukemia (AML).
  • Approximately 14 cases have been reported, including only 1 pediatric case.
  • Here we present the case of a 13-year-old boy with a new diagnosis of AML with some features of monocytic differentiation.
  • The patient was treated with standard AML chemotherapy plus gemtuzumab as part of a clinical trial.
  • To the best of our knowledge, this is the first description of a pediatric case of de novo AML with a stemline showing inv(16) along with 3'CBFB deletion, an abnormal clone revealing in addition a del(7)(q22q32), and another clone with a t(9;22;19)(q34;q11.2;p13.1) as an additional abnormality.
  • [MeSH-major] Chromosome Deletion. Chromosome Inversion. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 7. Chromosomes, Human, Pair 9. Fusion Proteins, bcr-abl / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20513535.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 16
  •  go-up   go-down


17. Veltroni M, Sainati L, Zecca M, Fenu S, Tridello G, Testi AM, Merlone AD, Buldini B, Leszl A, Lo Nigro L, Longoni D, Bernini G, Basso G, AIEOP-MDS Study Group: Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer; 2009 Mar;52(3):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
  • These studies have focused on the identification of abnormalities in the maturation pathway of antigen expression of myelo-monocytic cells, and characterization of blast populations.
  • The current article provides data concerning the blast phenotype in pediatric MDS.
  • PROCEDURE: We evaluated by multiparameter flow cytometry 26 MDS pediatric patients with more than 2% of blast cells at bone marrow morphological examination (17 de novo MDS and 9 secondary MDS) and 145 pediatric de novo acute myeloid leukemia (AML) cases (M3 excluded).
  • As control group, 12 healthy age-matched donors for allogenic bone marrow transplantation (BMD) and 6 regenerating bone marrow samples, collected from children with acute lymphoblastic leukemia (ALL) in remission after induction chemotherapy, were studied.
  • CONCLUSIONS: Our data suggest that the blasts phenotypic features can constitute a diagnostic and prognostic tool also for pediatric MDS.


18. Demircioğlu F, Oren H, Yilmaz S, Arslansoyu S, Eren S, Irken G: Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia. Pediatr Hematol Oncol; 2008 Apr-May;25(3):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
  • Chemotherapy-induced acral erythema or palmoplantar erythrodysesthesia syndrome is a well-defined reaction to some of the chemotherapeutic agents such as methotrexate, cytarabine, doxorubicin, fluorouracil, and bleomycin.
  • The authors present a case of acral erythema in a young patient with acute monoblastic leukemia to emphasize this high-dose chemotherapy-induced side effect, which is rarely seen in children and is usually self-limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythema / chemically induced. Leukemia, Monocytic, Acute / complications

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432504.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement